An experimental one-time gene editing therapy significantly lowered LDL cholesterol in an early-stage trial, raising hopes ...

Eli Lillys VERVE-102 gene therapy shows early trial success, cutting LDL cholesterol by up to 62 percent in high risk ...

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point ...

In an early-stage trial involving 35 high-risk patients, LDL or bad cholesterol fell by up to 62% after a single infusion of ...

In what could be one of the biggest breakthroughs in treating heart disease, a small study showed that an experimental ...

Eli Lilly said its experimental gene-editing therapy cut LDL, or “bad,” cholesterol by up to 62% in an early-stage trial, ...

If your doctor has ever told you to "keep an eye on your numbers," here's good news: The rules around what’s considered high ...

Here’s how one-shot PCSK9 gene base editing gene is predicted to lead to marked and durable reduction of LDL cholesterol ...

LLY's stock is still down year-to-date as AI-driven narratives have captured the bulk of investor attention and capital in ...

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

Eli Lilly (LLY) stock is in focus as the company's VERVE-102 gene-editing therapy cut “bad” LDL cholesterol up to 62% in an early-stage trial. Read more here.